Ichnos Glenmark Innovation (IGI) Presents First Clinical Data From Phase 1 Study Of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) With Durable Responses And Favorable Safety Profile In Patients With Heavily Pretreated Multiple Myeloma
Ichnos Glenmark Innovation (IGI) Presents First Clinical Data From Phase 1 Study Of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) With Durable Responses And Favorable Safety Profile In Patients With Heavily Pretreated Multiple Myeloma . (MENAFN - GlobeNewsWire - Nasdaq)   No dose-limiting toxicities were observed up to weekly subcutaneous doses of 1.2 mg/kg, with mostly mild Cytokine Release Syndrome, no cases of neurotoxicity, and ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108973901/Ichnos-Glenmark-Innovation-IGI-Presents-First-Clinical-Data-From-Phase-1-Study-Of-Trispecific-TREAT™-Antibody-ISB2001-Showing-High-Overall-Response-Rate-ORR-With-Durable-Responses-And-Favorable-Safety-Profile-In-Patients-With-Heavily-Pretreated-Multiple-Myeloma
2024-12-09
rss
(MENAFN - GlobeNewsWire - Nasdaq)   No dose-limiting toxicities were observed up to weekly subcutaneous doses of 1.2 mg/kg, with mostly mild Cytokine Release Syndrome, no cases of neurotoxicity, and ...
Ichnos Glenmark Innovation (IGI) Presents First Clinical Data From Phase 1 Study Of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) With Durable Responses And Favorable Safety Profile In Patients With Heavily Pretreated Multiple Myeloma